GlobeNewswire

Duo Security Launches UK Managed Service Provider and Security Solution Provider Programme

Dela

UK partner programme begins amid quadruple EMEA customer growth in past two years

LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Duo Security, one of the world's fastest growing cybersecurity providers, today announced the launch of its Managed Service Provider (MSP) and invitation-only Security Solution Provider programme in the United Kingdom. Duo's formal partner programme, which launched in the U.S. earlier this year, expands to the UK as the company has quadrupled its overall EMEA customer count from 450 to nearly 1,900 in the past two years.

Duo helps defend organizations against breaches by making security easy and effective. Anchored by its flagship two-factor authentication (2FA) app, Duo's cloud-based "Trusted Access" product offering verifies the identity of users and the health of their devices before granting them access to data and applications - helping prevent breaches and account takeover.

Unlike traditional security vendor programmes with tiered levels, Duo now offers a bespoke programme and enablement plans for security-centric UK-based solution providers invited to join the programme. The company expects more than half of its UK-based business to come through security solution provider and MSP partners as the programme progresses.

"Duo removes the pricing and implementation complexity of traditional partner models, allowing partners to be more profitable while providing their customers what they need to protect their data," said Matt Smith, Vice President of Worldwide Channels & Business Development. "Our comprehensive offering combined with our partner's expertise provides organizations a complete trusted access solution to protect their users, devices and applications without the typical complexity of most security products."

Duo's UK security solution provider business is led by EMEA Partner Manager Fiona Doak, a recent Duo hire with more than 26 years of experience in cybersecurity and technology. Doak previously held positions at RSA, Juniper Network, F5 Networks and WhiteHat Security.

"Duo brings a targeted, hyper-tailored approach to meeting the specific needs of partners and their customers," said Doak. "Each of the security partners we select has a strong practice with dedicated security architects and consultants, meaning the service they provide their customers is among the best in the industry."

Duo's UK Security Solution Provider programme already boasts partners such as Teneo, Saepio and Infosec Partners, and continues to expand with a select group of security-centric solution providers.

"It's so important today that security processes can be easily adopted and viewed by employees as business enablers, rather than a drag on productivity," said Marc Sollars, Chief Technology Officer at Teneo. "Our partnership with Duo means our customers can embed security much deeper into their company culture, because Duo's technology is such a pleasure to use. At Teneo, we've innovated around Duo's leading authentication technology to deliver a quick-to-implement and easy-to-use solution 'as a Service,' making security even simpler and intuitive for IT teams and employees. I deployed Duo in minutes via my own smartphone and was so amazed by how simple and effective it was, we immediately rolled it out across our own organization."

"The world's leading enterprises trust us to provide them sound advice and product recommendations, which is why we make sure each of our partners is of the highest caliber," said Andrew Pitt, Director at Saepio. "Duo's stellar reputation and proven track record of securing customers with an easy to use and effective product make it one of our hallmark product offerings for clients."

For more information, please visit https://duo.com/partners.

About Duo Security

Duo helps defend organizations against breaches through its easy and effective cloud-based Trusted Access product suite. The company verifies the identity of users and the health of their devices before granting them access to applications. Duo's intentional balance of security and usability has led the company to be a trusted partner to thousands of customers worldwide, including Dresser-Rand, Etsy, Facebook, K-Swiss, Random House, Yelp, Zillow, Paramount Pictures, and more. The Ann Arbor, Michigan-based company maintains offices in Austin, Texas; San Mateo, California; and London. Visit duo.com to find out more.

Media Contact
Meredith Corley & Jordan Fylonenko
Duo Security 
Press@duo.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Duo Security via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum